Sponsored by
(ENMD) By Michael Baron
Entremed (ENMD) is soaring more than 125 percent to $2.43 following news that the a study of the company's lead drug candidate Panzem found that its anti-tumor and anti-angiogenesis activity is dependent on its ability to inhibit microtubules and hypoxia inducible factor, or HIF. The company said the data establishes Panzem as a small molecule inhibitor of HIF, which is 'over-expressed in more than 70 percent of human cancers and metastases.'